Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGN-3005 UltraCAR-T in Advanced Platinum Resistant Ovarian Cancer
NCT03907527Phase 1Active, not recruiting
- Sponsor
- Precigen
- Start
- Apr 2019
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRGN-3005 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Precigen. Primary endpoints: Incidence of adverse events and Maximal Tolerated Dose of PRGN-3005 up to 28 days. Started Apr 2019; status: active, not recruiting.
02
Drugs
PRGN-3005
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03907527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907527.